Evidence map›Paper›PMID 32417755›Full record

ArticleThe Journal of biological chemistry2020

N- and C-terminal regions of αB-crystallin and Hsp27 mediate inhibition of amyloid nucleation, fibril binding, and fibril disaggregation.

Emily E Selig, Courtney O Zlatic, Dezerae Cox, Yee-Foong Mok, Paul R Gooley, Heath Ecroyd, Michael D W Griffin

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 40 citations in OpenAlex.

  1. Catechol-Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Competing chaperone pathways in α-synuclein disaggregation and aggregation dynamics.Protein science : a publication of the Protein Society · 2025
    Article
  7. Formation of a β-Endorphin Corona Mitigates Alzheimer's Amyloidogenesis.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Neural regeneration research · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. The role of heat shock proteins in preventing amyloid toxicity.Frontiers in molecular biosciences · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Emily E SeligDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-3012-6814
Courtney O ZlaticDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia.
Dezerae CoxDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-5345-8360
Yee-Foong MokDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia.
Paul R GooleyDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-0323-449X
Heath EcroydMolecular Horizons and the School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, New South Wales, Australia.ORCID 0000-0001-7574-0044
Michael D W GriffinDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia mgriffin@unimelb.edu.au.ORCID 0000-0001-9845-7735
The University of Melbourne · AUUniversity of Wollongong · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small heat-shock proteins (sHSPs) are ubiquitously expressed molecular chaperones that inhibit amyloid fibril formation; however, their mechanisms of action remain poorly understood. sHSPs comprise a conserved α-crystallin domain flanked by variable N- and C-terminal regions. To investigate the functional contributions of these three regions, we compared the chaperone activities of various constructs of human αB-crystallin (HSPB5) and heat-shock 27-kDa protein (Hsp27, HSPB1) during amyloid formation by α-synuclein and apolipoprotein C-II. Using an array of approaches, including thioflavin T fluorescence assays and sedimentation analysis, we found that the N-terminal region of Hsp27 and the terminal regions of αB-crystallin are important for delaying amyloid fibril nucleation and for disaggregating mature apolipoprotein C-II fibrils. We further show that the terminal regions are required for stable fibril binding by both sHSPs and for mediating lateral fibril-fibril association, which sequesters preformed fibrils into large aggregates and is believed to have a cytoprotective function. We conclude that although the isolated α-crystallin domain retains some chaperone activity against amyloid formation, the flanking domains contribute additional and important chaperone activities, both in delaying amyloid formation and in mediating interactions of sHSPs with amyloid aggregates. Both these chaperone activities have significant implications for the pathogenesis and progression of diseases associated with amyloid deposition, such as Parkinson's and Alzheimer's diseases.

Indexed as

alpha-Crystallin B Chainalpha-SynucleinAmyloidApolipoprotein C-IIHeat-Shock ProteinsHumansMolecular ChaperonesProtein Domainsalpha-Crystallin B Chainalpha-SynucleinAmyloidApolipoprotein C-IICRYAB protein, humanHeat-Shock ProteinsHSPB1 protein, humanMolecular ChaperonesSNCA protein, humanalpha-synuclein (α-synuclein)amyloidapolipoprotein C-IIchaperoneHsp27neurodegenerative diseaseprotein misfoldingsmall heat shock protein (sHsp)structure–functionαB-crystallin

Identifiers

PMID32417755
PMCPMC7380184
OpenAlexW3027470463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.